Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice.
about
Iron chelation and multiple sclerosisMechanisms of divalent metal toxicity in affective disordersDelayed emergence of behavioral and electrophysiological effects following juvenile ketamine exposure in miceSolid microparticles based on chitosan or methyl-β-cyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylateBrain Uptake of Neurotherapeutics after Intranasal versus Intraperitoneal Delivery in Mice.Iron-chelating agent desferrioxamine stimulates formation of neutrophil extracellular traps (NETs) in human blood-derived neutrophils.Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by "antioxidant" metal chelators: From ferroptosis to stroke.Intranasal therapeutic strategies for management of Alzheimer's disease.Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics.Improving drug delivery technology for treating neurodegenerative diseases.The Role of Hypoxia-Inducible Factor 1 in Mild Cognitive Impairment.Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease.Intranasal administration of CNS therapeutics to awake mice.Intranasal deferoxamine attenuates synapse loss via up-regulating the P38/HIF-1α pathway on the brain of APP/PS1 transgenic mice.Methods of Drug Delivery in Neurotrauma.Iron and Alzheimer's Disease: From Pathogenesis to Therapeutic ImplicationsUntangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration
P2860
Q27001743-09B1B33F-D661-4ADC-A0F2-493C7DA36257Q28384836-7BAC9084-61C7-4704-ADC1-EE6401171405Q30823871-DB1191BE-2F40-43F2-B7B4-429A76B200DCQ35088391-7E8777D6-26E0-4F12-90B9-7ED6C866DE0FQ36052412-A6B9BD7C-2527-44FB-8745-0DAAA9B8DD14Q37626825-5AF37EF7-4752-443D-B0B1-428E690D7AF6Q38078689-E8946031-BBE1-4739-B3E2-9DAC497ABA4DQ38176935-078DA5E5-4DC8-47F2-B518-B963160ABEF4Q38627193-11DBD960-480A-467A-82AD-64CA9B899EE9Q38769989-0951FC09-B8C4-4DE9-9E14-8F46FA0C18AFQ39011807-8EFE83BC-DFA8-4729-A893-21C1F0AEC68EQ39042377-9685C24B-4B5B-4988-8D70-17315BD5FFF0Q40678352-F2304389-46F1-4E65-9DE9-899EB2E02E6DQ41516212-B0D44847-AFFC-41CA-94DC-BC077D27C13CQ48525432-2A9670FD-6457-405F-9B0C-88168E33DCCAQ58754278-CC038E73-9CC6-4582-A835-13B2EA3CB91FQ58769184-52BC4F97-2DE9-45ED-8DD0-00B7033A985A
P2860
Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Intranasal deferoxamine improv ...... in P301L tau transgenic mice.
@en
Intranasal deferoxamine improv ...... in P301L tau transgenic mice.
@nl
type
label
Intranasal deferoxamine improv ...... in P301L tau transgenic mice.
@en
Intranasal deferoxamine improv ...... in P301L tau transgenic mice.
@nl
prefLabel
Intranasal deferoxamine improv ...... in P301L tau transgenic mice.
@en
Intranasal deferoxamine improv ...... in P301L tau transgenic mice.
@nl
P2093
P2860
P1476
Intranasal deferoxamine improv ...... in P301L tau transgenic mice.
@en
P2093
A M Baillargeon
D B Renner
K A Sparley
L R Hanson
N S Hoerster
P2860
P2888
P304
P356
10.1007/S00221-012-3101-0
P577
2012-05-01T00:00:00Z